Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2007

01-02-2007 | Original Article

The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study

Authors: David Tendler, Sauyu Lin, William S. Yancy Jr., John Mavropoulos, Pam Sylvestre, Don C. Rockey, Eric C. Westman

Published in: Digestive Diseases and Sciences | Issue 2/2007

Login to get access

Abstract

Nonalcoholic fatty liver disease is an increasingly common condition that may progress to hepatic cirrhosis. This pilot study evaluated the effects of a low-carbohydrate, ketogenic diet on obesity-associated fatty liver disease. Five patients with a mean body mass index of 36.4 kg/m2 and biopsy evidence of fatty liver disease were instructed to follow the diet (<20 g/d of carbohydrate) with nutritional supplementation for 6 months. Patients returned for group meetings biweekly for 3 months, then monthly for the second 3 months. The mean weight change was −12.8 kg (range 0 to −25.9 kg). Four of 5 posttreatment liver biopsies showed histologic improvements in steatosis (P=.02) inflammatory grade (P=.02), and fibrosis (P=.07). Six months of a low-carbohydrate, ketogenic diet led to significant weight loss and histologic improvement of fatty liver disease. Further research is into this approach is warranted.
Literature
1.
2.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Bopariai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 116:1413PubMedCrossRef Matteoni CA, Younossi ZM, Gramlich T, Bopariai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: A spectrum of clinical pathological severity. Gastroenterology 116:1413PubMedCrossRef
3.
go back to reference Hilden M, Christoffersen P, Juhl E, Dalgaard JB (1977) Liver histology in a ‘normal’ population—examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12:593–597PubMedCrossRef Hilden M, Christoffersen P, Juhl E, Dalgaard JB (1977) Liver histology in a ‘normal’ population—examination of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12:593–597PubMedCrossRef
4.
go back to reference Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity. An autopsy study with analysis of risk factors. Hepatology 12:1006–1010 Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity. An autopsy study with analysis of risk factors. Hepatology 12:1006–1010
5.
go back to reference Crespo J, Fernandez-Gil P, Hernandez-Guerra M, Cayon A, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F (2001) Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 11:254–257PubMedCrossRef Crespo J, Fernandez-Gil P, Hernandez-Guerra M, Cayon A, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F (2001) Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 11:254–257PubMedCrossRef
6.
go back to reference Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727PubMedCrossRef
8.
go back to reference Sheth SG, Gordon FD, Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126:137–145PubMed Sheth SG, Gordon FD, Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126:137–145PubMed
9.
go back to reference Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME (1995) Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 22:1399–1403PubMedCrossRef Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, Gornbein J, Ament ME (1995) Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 22:1399–1403PubMedCrossRef
10.
go back to reference Harrison SA, Diehl AM (2002) Fat and the liver—a molecular overview. Semin Gastrointest Dis 13:3–16PubMed Harrison SA, Diehl AM (2002) Fat and the liver—a molecular overview. Semin Gastrointest Dis 13:3–16PubMed
11.
go back to reference Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379PubMedCrossRef Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379PubMedCrossRef
12.
go back to reference Pagano G, Pacini G, Musso G, Gambino G, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M (2002) Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 35:367PubMedCrossRef Pagano G, Pacini G, Musso G, Gambino G, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M (2002) Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 35:367PubMedCrossRef
13.
go back to reference Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358:893–894PubMedCrossRef Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358:893–894PubMedCrossRef
14.
go back to reference Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519–525PubMedCrossRef Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519–525PubMedCrossRef
15.
go back to reference Acosta RC, Molina EG, O’Brien CB, et al (2001) The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 120A:546CrossRef Acosta RC, Molina EG, O’Brien CB, et al (2001) The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 120A:546CrossRef
16.
go back to reference Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S (2003) A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:2082–2090PubMedCrossRef Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S (2003) A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348:2082–2090PubMedCrossRef
17.
go back to reference Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP (2005) Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 142:403–411PubMed Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP (2005) Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med 142:403–411PubMed
18.
go back to reference Yancy WS, Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC (2004) A randomized, controlled trial of a low-carbohydrate, ketogenic diet versus a low-fat diet for obesity and hyperlipidemia. Ann Intern Med 140:769–777PubMed Yancy WS, Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC (2004) A randomized, controlled trial of a low-carbohydrate, ketogenic diet versus a low-fat diet for obesity and hyperlipidemia. Ann Intern Med 140:769–777PubMed
19.
go back to reference Phinney SD, Bistrian BR, Wolfe RR, Blackburn GL (1983) The human response to chronic ketosis without caloric restriction: physical and biochemical adaptation. Metabolism 32:757–768PubMedCrossRef Phinney SD, Bistrian BR, Wolfe RR, Blackburn GL (1983) The human response to chronic ketosis without caloric restriction: physical and biochemical adaptation. Metabolism 32:757–768PubMedCrossRef
20.
go back to reference Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis. A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis. A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRef
21.
go back to reference Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537–544PubMedCrossRef Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537–544PubMedCrossRef
22.
go back to reference Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS (2005) One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: A pilot study. Am J Gastroenterol 100:1072–1081PubMedCrossRef Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS (2005) One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: A pilot study. Am J Gastroenterol 100:1072–1081PubMedCrossRef
23.
go back to reference Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T (2004) Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49:1578–1583PubMedCrossRef Solga S, Alkhuraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T (2004) Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 49:1578–1583PubMedCrossRef
24.
go back to reference McDevitt RM, Bott SJ, Harding M, Coward WA, Bluck LJ, Prentice AM (2001) De novo lipogenesis during controlled overfeeding with sucrose or glucose in lean and obese women. Am J Clin Nutr 74:737–746PubMed McDevitt RM, Bott SJ, Harding M, Coward WA, Bluck LJ, Prentice AM (2001) De novo lipogenesis during controlled overfeeding with sucrose or glucose in lean and obese women. Am J Clin Nutr 74:737–746PubMed
25.
go back to reference Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L (2005) Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 54:1907–1913PubMed Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L (2005) Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 54:1907–1913PubMed
26.
go back to reference Nielsen SJ, Popkin BM (2004) Changes in beverage intake between 1977 and 2001. Am J Prev Med 27:205–210PubMedCrossRef Nielsen SJ, Popkin BM (2004) Changes in beverage intake between 1977 and 2001. Am J Prev Med 27:205–210PubMedCrossRef
27.
go back to reference Ludwig DS, Peterson KE, Gortmaker SL (2001) Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 357:505–508PubMedCrossRef Ludwig DS, Peterson KE, Gortmaker SL (2001) Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 357:505–508PubMedCrossRef
Metadata
Title
The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study
Authors
David Tendler
Sauyu Lin
William S. Yancy Jr.
John Mavropoulos
Pam Sylvestre
Don C. Rockey
Eric C. Westman
Publication date
01-02-2007
Published in
Digestive Diseases and Sciences / Issue 2/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9433-5

Other articles of this Issue 2/2007

Digestive Diseases and Sciences 2/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.